Table 4.

Adverse events "likely" or "definitely" related to study treatment

System organ class	Preferred term	Synvisc-one n = 32	Hydros n = 32	Hydros-TA n = 34
Musculoskeletal and Connective Tissue disorders, n (%)	Arthralgia	5 (16)	4 (13)	1 (3)
	Joint Stiffness	2 (6)	2 (6)	0
	Joint Swelling	1 (3)	0	0
General Disorders and Administration Site conditions, n (%)	Application Site Warmth	1 (3)	0	0
	Injection Site Warmth	0	0	1 (3)
	Injection Site Movement Impairment	0	1 (3)	0
	Injection site pain	0	0	1 (3)
Total Related Adverse Events, n (%)	NA	9 (28)	7 (22)	3 (9)